{
    "clinical_study": {
        "@rank": "134489", 
        "arm_group": [
            {
                "arm_group_label": "Triple therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Group (A): triple therapy for 14 days D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid"
            }, 
            {
                "arm_group_label": "non-bismuth quadruple therapy", 
                "arm_group_type": "Experimental", 
                "description": "Group (B): non-bismuth quadruple therapy for 10 days: lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg bid"
            }, 
            {
                "arm_group_label": "bismuth quadruple therapy for 10 days", 
                "arm_group_type": "Experimental", 
                "description": "Group (C): bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid + colloidal bismuth subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid"
            }
        ], 
        "brief_summary": {
            "textblock": "Whether non-bismuth quadruple therapy (concomitant therapy) is more effective than bismuth\n      quadruple therapy or triple therapy for 14 days remains unknown.\n\n      Therefore, we aim to compare the eradication rates and long term re-infection rates of\n      quadruple therapy for 10 days versus non-bismuth quadruple therapy for 10 days vs. triple\n      therapy for 14 days.\n\n      Methods: This will be a multi-center, open labeled, randomized control trial Patients: H.\n      pylori infected patients who have willingness to receive eradication therapy\n\n      Testing for H. pylori infection Before First Line Ttreatment\n\n      (1)Any two positive of CLO test, histology, serology and culture or a positive UBT will be\n      considered as H. pylori infected\n\n      After First Line Treatment: C13-UBT will be used to assess the existence of H. pylori 6-8\n      weeks after first line therapy.\n\n      Long term reinfection: C13-UBT will be used to assess the recurrence of H. pylori 1 year\n      after eradication therapy"
        }, 
        "brief_title": "Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Helicobacter Pylori Infection", 
        "condition_browse": {
            "mesh_term": "Helicobacter Infections"
        }, 
        "detailed_description": {
            "textblock": "First line therapy: open labeled, randomized control trial, randomized into one of the three\n      groups Group (A): triple therapy for 14 days D1-D14: (lansoprazole 30mg + clarithromycin\n      500mg + amoxicillin 1gm) bid Group (B): non-bismuth quadruple therapy for 10 days D1-D10:\n      lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg\n      bid Group (C): bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid +\n      colloidal bismuth subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid\n\n      Second line therapy: patients who fail from first line treatment will be rescue with the\n      following treatment Group (A) Patient who fail from triple therapy will be retreated with\n      bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid + colloidal bismuth\n      subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid Group (B) Patient\n      who fail from non-bismuth quadruple therapy will be retreated with bismuth quadruple therapy\n      for 10 days D1-D10: lansoprazole 30mg bid + colloidal bismuth subcitrate 300mg tid +\n      metronidazole 500mg tid + tetracycline 500mg tid Group (C) Patients who fail from bismuth\n      quadruple therapy will be retreated with non-bismuth quadruple therapy for 10 days D1-D10:\n      lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg\n      bid"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients aged greater than 20 years who have H. pylori infection without prior eradication\n        therapy and are willing to receive the sequential therapy will be eligible for enrolment.\n        Written informed consents will be obtained from all patients prior to enrollment.\n\n        Exclusion Criteria:\n\n        Patients will be excluded from the study if any one of the following criteria is present:\n        (1) children and teenagers aged less than 20 years, (2) history of gastrectomy, (3)gastric\n        malignancy, including adenocarcinoma and lymphoma, (4) previous allergic reaction to\n        antibiotics (amoxicillin, clarithromycin, metronidazole, or levofloxacin) and prompt pump\n        inhibitors (lansoprazole), (5)contraindication to treatment drugs, (6) pregnant or\n        lactating women, (7) severe concurrent diseases, and (8) Patients who cannot give informed\n        consent by himself or herself."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "1200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01906879", 
            "org_study_id": "201304017MINB"
        }, 
        "intervention": {
            "arm_group_label": [
                "Triple therapy", 
                "non-bismuth quadruple therapy", 
                "bismuth quadruple therapy for 10 days"
            ], 
            "description": "triple therapy, quadruple therapy, non-bismuth quadruple therapy", 
            "intervention_name": "triple, quadruple, non-bismuth quadruple therapy", 
            "intervention_type": "Drug", 
            "other_name": [
                "Group (A): triple therapy for 14 days", 
                "Group (B): non-bismuth quadruple therapy for 10 days", 
                "Group (C): bismuth quadruple therapy for 10 days"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Bismuth", 
                "Clarithromycin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 21, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Jyh-Ming Liou, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "10002"
                    }, 
                    "name": "Ming-Shiang Wu"
                }, 
                "investigator": [
                    {
                        "last_name": "Ming-Shiang Wu, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jyh-Ming Liou, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Mei-Jyh Chen, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Chien-Chun Chen, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Chieh-Chang Chen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Yun-Lin County", 
                        "country": "Taiwan"
                    }, 
                    "name": "National Taiwan University Hospital, Yun-Lin Branch"
                }, 
                "investigator": [
                    {
                        "last_name": "Chieh-Chang Chan, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ji-Yuh Lee, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Yu-Jen Fang, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "3", 
        "official_title": "Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial", 
        "other_outcome": {
            "description": "Eradication rates in the second line treatment in the three treatment groups\nOverall eradication rates after first line and second line treatment in the three treatment groups\nAntibiotic resistance of gut flora after first line and second line treatments in the three treatment groups\nChanges of gut microbiota in the three treatment groups\nRe-infection rate one year after eradication therapy", 
            "measure": "Reinfection rate", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "overall_contact": {
            "email": "dtmed046@yahoo.com.tw", 
            "last_name": "Jyh-Ming Liou, MD, PhD"
        }, 
        "overall_official": {
            "affiliation": "National Taiwan University Hospital, Taipei, Taiwan", 
            "last_name": "Ming-Shiang Wu, MD. PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Department of Health: Taiwan", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Eradication rate in the first line according to intention to treat (ITT) and per-protocol (PP) analysis in the three treatment groups", 
            "measure": "Eradication rate for H. pylori", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01906879"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Taiwan University Hospital", 
            "investigator_full_name": "National Taiwan University Hospital", 
            "investigator_title": "Department of Internal Medicine, National Taiwan University Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "(1)\tIncidence of adverse effects in the first line therapy in the three treatment groups", 
            "measure": "Adverse effects of each treatments", 
            "safety_issue": "Yes", 
            "time_frame": "2 weeks"
        }, 
        "source": "National Taiwan University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Taiwan University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}